Numinus Provides Bi-Weekly Update on Annual Filings
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) provided an update on its previously announced management cease trade order (MCTO) regarding the filing of its audited annual financial statements, management discussion and analysis (MD&A), and annual information form (AIF) for the fiscal year ending August 31, 2024. The British Columbia Securities Commission granted the MCTO on December 2, 2024, under National Policy 12-203 (NP 12-203). This order restricts the company's CEO and CFO from trading in company securities until the filings are complete and the MCTO is revoked.
During this period, Numinus will halt share buy-back activities and refrain from issuing or acquiring securities from insiders or employees. Shareholders, however, can continue to trade their securities. The company anticipates finalizing the filings by January 28, 2025, and will issue a news release upon completion. Until then, Numinus will comply with NP 12-203 by issuing bi-weekly default status reports.
Since the last announcement, Numinus confirms it has met its obligations under NP 12-203, has not experienced any new defaults, is not undergoing insolvency proceedings, and has no undisclosed material information.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) ha fornito un aggiornamento sul suo provvedimento di cessazione del commercio da parte della dirigenza (MCTO) precedentemente annunciato riguardo la presentazione dei suoi bilanci annuali certificati, discussione e analisi della direzione (MD&A) e modulo informativo annuale (AIF) per l'anno fiscale che si chiude il 31 agosto 2024. La British Columbia Securities Commission ha concesso il MCTO il 2 dicembre 2024, ai sensi della National Policy 12-203 (NP 12-203). Questo provvedimento impedisce al CEO e al CFO dell'azienda di commerciare titoli societari fino a quando le presentazioni non saranno complete e il MCTO non sarà revocato.
Durante questo periodo, Numinus sospenderà le attività di riacquisto di azioni e si asterrà dall'emissione o dall'acquisto di titoli da parte di insider o dipendenti. Tuttavia, gli azionisti possono continuare a negoziare i loro titoli. L'azienda prevede di finalizzare le presentazioni entro il 28 gennaio 2025 e emetterà un comunicato stampa al termine. Fino ad allora, Numinus si atterrà alla NP 12-203 emettendo rapporti bimestrali sullo stato di default.
Da ultimo annuncio, Numinus conferma di aver rispettato i suoi obblighi ai sensi della NP 12-203, di non aver subito nuovi inadempimenti, di non essere in corso di procedimenti di insolvenza e di non avere informazioni materiali non divulgate.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) proporcionó una actualización sobre su anteriormente anunciada orden de cesación de comercio por parte de la dirección (MCTO) relacionada con la presentación de sus estados financieros anuales auditados, discusión y análisis de la dirección (MD&A) y formulario de información anual (AIF) para el año fiscal que finaliza el 31 de agosto de 2024. La British Columbia Securities Commission aprobó el MCTO el 2 de diciembre de 2024, bajo la National Policy 12-203 (NP 12-203). Esta orden restringe al CEO y al CFO de la compañía de comerciar en valores de la empresa hasta que las presentaciones estén completas y el MCTO sea revocado.
Durante este período, Numinus detendrá las actividades de recompra de acciones y se abstendrá de emitir o adquirir valores de parte de personas relacionadas o empleados. Sin embargo, los accionistas pueden continuar comerciando sus valores. La empresa prevé finalizar las presentaciones para el 28 de enero de 2025 y emitirá un comunicado de prensa al respecto. Hasta entonces, Numinus cumplirá con la NP 12-203 emitiendo informes de estatus de incumplimiento cada dos semanas.
Desde el último anuncio, Numinus confirma que ha cumplido con sus obligaciones bajo la NP 12-203, no ha experimentado nuevos incumplimientos, no se encuentra en procedimientos de insolvencia y no tiene información material no divulgada.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF)는 2024년 8월 31일 종료되는 회계 연도에 대한 감사된 연간 재무제표, 경영진 토론 및 분석(MD&A), 연간 정보 양식(AIF)의 제출과 관련하여 이전에 발표된 경영진 거래 중지 명령 (MCTO)에 대한 업데이트를 제공했습니다. 브리티시컬럼비아 증권 위원회는 2024년 12월 2일에 MCTO를 승인했으며, 이는 국가 정책 12-203 (NP 12-203)에 따른 것입니다. 이 명령은 CEO와 CFO가 서류 제출이 완료되고 MCTO가 철회될 때까지 회사 유가증권 거래를 제한합니다.
이 기간 동안 Numinus는 자사 주식을 매입하는 활동을 중단하고 내부자 또는 직원으로부터 유가증권을 발행하거나 인수하는 것을 자제할 것입니다. 그러나 주주들은 자신들의 유가증권을 계속 거래할 수 있습니다. 회사는 2025년 1월 28일까지 서류 제출을 완료할 것으로 예상하고 있으며, 완료 시 보도자료를 발행할 것입니다. 그때까지 Numinus는 NP 12-203을 준수하며 격주로 기본 상태 보고서를 발행할 것입니다.
지난 발표 이후, Numinus는 NP 12-203에 따른 의무를 이행했으며 새로운 기본 상황을 겪지 않았고, 지급불능 절차를 진행 중이지 않으며, 공개되지 않은 중대한 정보가 없다고 확인했습니다.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) a fourni une mise à jour concernant son ordre de cessation d'opérations par la direction (MCTO) précédemment annoncé, concernant le dépôt de ses états financiers annuels audités, discussion et analyse de la direction (MD&A) et formulaire d'information annuel (AIF) pour l'exercice fiscal se terminant le 31 août 2024. La British Columbia Securities Commission a accordé le MCTO le 2 décembre 2024, conformément à la National Policy 12-203 (NP 12-203). Cet ordre interdit au PDG et au directeur financier de négocier des titres de l'entreprise jusqu'à ce que les dépôts soient complets et que le MCTO soit révoqué.
Durant cette période, Numinus mettra un terme aux activités de rachat d'actions et s'abstiendra d'émettre ou d'acquérir des titres auprès de personnes liées ou d'employés. Cependant, les actionnaires peuvent continuer à négocier leurs titres. L'entreprise prévoit de finaliser les dépôts d'ici le 28 janvier 2025 et publiera un communiqué une fois cela fait. D'ici là, Numinus respectera la NP 12-203 en émettant des rapports d'état de défaut toutes les deux semaines.
Depuis la dernière annonce, Numinus confirme avoir respecté ses obligations en vertu de la NP 12-203, n'avoir connu aucun nouveau défaut, ne pas être en cours de procédure d'insolvabilité et ne pas avoir d'informations matérielles non divulguées.
Numinus Wellness (TSX: NUMI, OTCQX: NUMIF) hat ein Update zu seiner zuvor angekündigten Handelseinschränkung durch das Management (MCTO) bezüglich der Einreichung seiner prüften Jahresabschlüsse, Management-Diskussion und -Analyse (MD&A) und des Jahresinformationsformulars (AIF) für das am 31. August 2024 endende Geschäftsjahr gegeben. Die British Columbia Securities Commission hat die MCTO am 2. Dezember 2024 gemäß der National Policy 12-203 (NP 12-203) genehmigt. Diese Anordnung schränkt den CEO und CFO des Unternehmens ein, bis die Einreichungen abgeschlossen und die MCTO aufgehoben ist, in Unternehmenswertpapiere zu handeln.
Während dieses Zeitraums wird Numinus die Aktienrückkaufaktivitäten einstellen und sich davon abhalten, Wertpapiere von Insider oder Mitarbeitern auszugeben oder zu erwerben. Aktionäre können jedoch weiterhin ihre Wertpapiere handeln. Das Unternehmen plant, die Einreichungen bis zum 28. Januar 2025 abzuschließen und wird nach Abschluss eine Pressemitteilung herausgeben. Bis dahin wird Numinus der NP 12-203 nachkommen, indem es alle zwei Wochen Statusberichte über den Verzug veröffentlicht.
Seit der letzten Ankündigung bestätigt Numinus, dass es seinen Verpflichtungen nach NP 12-203 nachgekommen ist, keine neuen Verzögerungen erlitten hat, sich nicht in Insolvenzverfahren befindet und keine nicht offengelegten wesentlichen Informationen hat.
- Shareholders can continue trading their securities despite the MCTO.
- Numinus anticipates completing the filings by January 28, 2025.
- The CEO and CFO are restricted from trading company securities until filings are complete.
- Numinus has halted share buy-back activities during the MCTO period.
Further to the Company's news release dated December 3, 2024 (the "Announcement"), the Company's principal regulator, the British Columbia Securities Commission (the "Commission"), granted the MCTO on December 2, 2024, under National Policy 12-203 – Management Cease Trader Orders ("NP 12-203"). Pursuant to the MCTO, the Chief Executive Officers and the Chief Financial Officer of the Company may not trade in securities of the Company until such time as the Company files the Annual Filings and the Commission revokes the MCTO. During this period, the Company will cease any share buy-back activities under its normal course issuer bid, and has undertaken not to, directly or indirectly, issue or acquire securities from an insider or employee of the Company.
The MCTO does not affect the ability of shareholders to trade their securities.
The Company's Board of Directors and management are continuing to work with its accounting team to prepare the Annual Filings as soon as practicable. The delay in filing the Annual Filings is a result of unexpected delays experienced by the Company. It is the Company's reasonable expectation that the Annual Filings will be finalized by January 28, 2025.
The Company will issue a news release announcing completion of filing of the Annual Filings at such time as they are completed and filed. Until the Company files the Annual Filings, it will comply with the alternative information guidelines set out under NP 12-203, including issuing bi-weekly default status reports by way of news releases, which will be filed on SEDAR+.
In addition, the Company confirms that since the date of the Announcement: (i) there has been no failure by the Company in fulfilling its stated intentions with respect to satisfying the provisions of the alternative information guidelines set out in NP 12-203; (ii) there has not been any other specified default by the Company under NP 12-203; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no other material information concerning the affairs of the Company that has not been generally disclosed.
About Numinus
Numinus Wellness Inc. (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms of depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society. Learn more at www.numinus.com and follow us on LinkedIn, Facebook, and Instagram.
Forward Looking Statements
Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", and "intend" and statements that an event "may", "will", "should", "could" or "might" occur or other similar expressions. In particular, and without limitation, this news release contains forward-looking statements respecting the Company's reasonable expectation that the Annual Filings will be finalized by January 28, 2025 and the Company's compliance with the MCTO and NP 12-203. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements, including the results of further research into MDMA, if any, the FDA and other regulators' decisions in respect of MDMA and other psychedelic medications, restrictions that may be placed on the use of psychedelic compounds by regulatory authorities; safety and efficacy of psychedelic-assisted therapy; acceptance, uptake and commercialization of psychedelic assisted therapy, if any; dependence on obtaining regulatory approvals, and other risks that are set forth in our annual information form dated November 29, 2023, and available on SEDAR at www.sedarplus.ca. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. Numinus does not undertake any obligation to update forward-looking statements even if circumstances or management's estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.
View original content:https://www.prnewswire.com/news-releases/numinus-provides-bi-weekly-update-on-annual-filings-302348512.html
SOURCE Numinus Wellness Inc.
FAQ
What is the impact of the NUMIF management cease trade order?
Can shareholders trade NUMIF shares during the MCTO?
When does Numinus expect to complete its annual filings?
What are the consequences of the MCTO for NUMIF?
Why was the NUMIF MCTO issued?
What steps is Numinus taking during the MCTO period?
